1193447-34-5

Basic information

• Product Name: (T-4)-[(1E,6E)-1,7-bis[4-(Dimethylamino)phenyl]-1,6-heptadiene-3,5-dionato-?O3,?O5]difluoroboron
• Synonyms: (T-4)-[(1E,6E)-1,7-bis[4-(Dimethylamino)phenyl]-1,6-heptadiene-3,5-dionato-?O3,?O5]difluoroboron;CRANAD 2
• CAS NO: 1193447-34-5
• Molecular Formula: C23H25BF2N2O2
• Molecular Weight: 410.2646064
• Mol File: 1193447-34-5.mol
• Article Data: 0

Chemical Properties

• Appearance: , dark blue to black/
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble0.2mg/mL, clear (warmed)
• CAS DataBase Reference: (T-4)-[(1E,6E)-1,7-bis[4-(Dimethylamino)phenyl]-1,6-heptadiene-3,5-dionato-?O3,?O5]difluoroboron(CAS DataBase Reference)
• NIST Chemistry Reference: (T-4)-[(1E,6E)-1,7-bis[4-(Dimethylamino)phenyl]-1,6-heptadiene-3,5-dionato-?O3,?O5]difluoroboron(1193447-34-5)
• EPA Substance Registry System: (T-4)-[(1E,6E)-1,7-bis[4-(Dimethylamino)phenyl]-1,6-heptadiene-3,5-dionato-?O3,?O5]difluoroboron(1193447-34-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 1193447-34-5(Hazardous Substances Data)

Usage

Description

Cranad-2, also known as a near-infrared probe, is a compound designed to specifically bind to Aβ40 aggregates, which are associated with Alzheimer's disease. It has the unique ability to elicit an emission blue shift upon binding, making it a valuable tool for detecting and studying these aggregates.

Uses

Used in Alzheimer's Disease Research:
Cranad-2 is used as a diagnostic tool for detecting Aβ40 aggregates in Alzheimer's disease. Its ability to bind specifically to these aggregates and elicit an emission blue shift allows researchers to visualize and study the distribution and characteristics of these aggregates in the brain.
Used in Drug Development:
Cranad-2 can also be used in the development of therapeutic agents targeting Aβ40 aggregates. By understanding how Cranad-2 interacts with these aggregates, researchers can gain insights into the molecular mechanisms underlying their formation and potentially develop drugs that can disrupt or prevent these interactions, thereby slowing or halting the progression of Alzheimer's disease.
Used in APP-PS1 Transgenic Mice Model:
Cranad-2 has been demonstrated to bind to plaques in APP-PS1 transgenic mice, an animal model used to study Alzheimer's disease. This application allows researchers to use Cranad-2 as a tool for studying the progression of the disease and the effectiveness of potential therapeutic interventions in a controlled experimental setting.